A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia

Blood

Volumn 119, Issue 1, 2012, Pages 196-205

  Sunter, Nicola J ^a   Scott, Kathryn ^b   Hills, Robert ^c   Grimwade, David ^d   Taylor, Sheila ^b   Worrillow, Lisa J ^b   Fordham, Sarah E ^a   Forster, Victoria J ^a   Jackson, Graham ^e   Bomken, Simon ^a   Jones, Gail ^e   Allan, James M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BINDING SITE; CHILD; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAZARD RATIO; HUMAN; HUMAN CELL; INFANT; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; NEWBORN; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROMYELOCYTIC LEUKEMIA; SCHOOL CHILD;

EID: 84855589943     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-349803     Document Type: Article

References (35)

1. de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111(7):3395-3402.
2. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood. 1999;93(12):4131-4143. (Pubitemid 29279255)
3. Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118(5):1248-1254.
4. Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009;30(2):180-192.
5. Hao Z, Duncan GS, Seagal J, et al. Fas receptor expression in germinal-center B cells is essential for T and B lymphocyte homeostasis. Immunity. 2008;29(4):615-627.
6. Akgul C, Edwards SW. Regulation of neutrophil apoptosis via death receptors. Cell Mol Life Sci. 2003;60(11):2402-2408. (Pubitemid 37487260)
7. Clarke MC, Savill J, Jones DB, Noble BS, Brown SB. Compartmentalized megakaryocyte death generates functional platelets committed to caspase-independent death. J Cell Biol. 2003;160(4):577-587. (Pubitemid 36254395)
8. Bouillet P, O'Reilly LA. CD95, BIM and T cell homeostasis. Nat Rev Immunol. 2009;9(7):514-519.
9. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 1996;2(5):574-577. (Pubitemid 26150685)
10. Sibley K, Rollinson S, Allan JM, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 2003;63(15):4327-4330. (Pubitemid 36950998)
11. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92(7):2322-2333. (Pubitemid 28452973)
12. Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010;28(4):586-595.
13. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369-377.
14. Sanz MA, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood. 2008;112(8):3130-3134.
15. Wang ZG, Ruggero D, Ronchetti S, et al. PML is essential for multiple apoptotic pathways. Nat Genet. 1998;20(3):266-272. (Pubitemid 28507671)
16. Tao RH, Berkova Z, Wise JF, et al. PMLRARα binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivo. Blood. 2011;118(11):3107-3118.
17. Kim KM, Lee K, Hong YS, Park HY. Fas-mediated apoptosis and expression of related genes in human malignant hematopoietic cells. Exp Mol Med. 2000;32(4):246-254. (Pubitemid 32041708)
18. Fulda S, Scaffidi C, Pietsch T, et al. Activation of the CD95 (APO-1/Fas) pathway in drug- and gamma-irradiation-induced apoptosis of brain tumor cells. Cell Death Differ. 1998;5(10):884-893. (Pubitemid 28484399)
19. Muller M, Scaffidi CA, Galle PR, Stremmel W, Krammer PH. The role of p53 and the CD95 (APO-1/Fas) death system in chemotherapy-induced apoptosis. Eur Cytokine Netw. 1998;9(4):685-686. (Pubitemid 29033938)
20. Landowski TH, Gleason-Guzman MC, Dalton WS. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood. 1997;89(6):1854-1861. (Pubitemid 27132098)
21. Tourneur L, Delluc S, Levy V, et al. Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome. Cancer Res. 2004;64(21):8101-8108.
22. Mehta PA, Gerbing RB, Alonzo TA, et al. FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A Children's Oncology Group report. Clin Cancer Res. 2008;14(23):7896-7899.
23. Gonzalez M, Barragan E, Bolufer P, et al. Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group. Br J Haematol. 2001;114(1):99-103. (Pubitemid 32702639)
24. Gallagher RE, Willman CL, Slack JL, et al. Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood. 1997;90(4):1656-1663. (Pubitemid 27355440)
25. Guglielmi C, Martelli MP, Diverio D, et al. Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome: a cooperative Italian study on 196 cases. Br J Haematol. 1998;102(4):1035-1041. (Pubitemid 28410536)
26. Salih HR, Starling GC, Brandl SF, et al. Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas ligand (CD178) expression. Br J Haematol. 2002;117(1):76-85. (Pubitemid 34304424)
27. Kikuchi H, Iizuka R, Sugiyama S, et al. Monocytic differentiation modulates apoptotic response to cytotoxic anti-Fas antibody and tumor necrosis factor alpha in human monoblast U937 cells. J Leukoc Biol. 1996;60(6):778-783. (Pubitemid 27041668)
28. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia: the European APL Group. Blood. 1999;94(4):1192-1200. (Pubitemid 29380399)
29. Kelaidi C, Chevret S, de Botton S, et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol. 2009;27(16):2668-2676.
30. Ades L, Chevret S, de Botton S, et al. Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia. 2005;19(2):230-233. (Pubitemid 40220587)
31. Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009;106(9):3342-3347.
32. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107(9):3469-3473.
33. Krammer PH, Dhein J, Walczak H, et al. The role of APO-1-mediated apoptosis in the immune system. Immunol Rev. 1994;142:175-191.
34. Gurrieri C, Capodieci P, Bernardi R, et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst. 2004;96(4):269-279. (Pubitemid 38256272)
35. Tallman MS, Manji GA. Don't just stand there, do something. Strategies for the prevention of early death in acute promyelocytic leukemia: a commentary. Blood Cells Mol Dis. 2011;46(2):173-174.